Plain-English translation of NCT06565195 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called that is injected directly into your spinal fluid to see if it is safe and how your body responds to it. The study will first test the medication in healthy volunteers who receive one injection, and then in people with early Parkinson's disease who receive two injections spaced 12 to 24 weeks apart. Researchers want to understand whether this treatment is tolerable and how it works in the body.
Parkinson's disease causes progressive damage to the brain, and current treatments don't slow or stop this progression. By delivering this medication directly to the spinal fluid, researchers hope it may reach and protect the brain in a new way that could help people with early-stage disease.
You likely qualify if…
You likely don't qualify if…
If you are a healthy volunteer, you will receive one injection of the medication or placebo into your spinal fluid and then be monitored for up to 52 weeks with clinic visits and tests. If you have Parkinson's disease, you will receive two injections spaced 12 to 24 weeks apart, also into your spinal fluid, followed by monitoring visits and tests for up to 52 weeks after your second injection. Throughout the study, you will have blood tests, heart monitoring, and other safety assessments to make sure the treatment is well tolerated.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Japan